$RGBPP One critical factor in the company’s favor is their agreement with Eli Lilly and Co (NYSE:LLY) as part of their Innovation Drug Discovery Program, which allows Regen to receive compounds from Lilly for drug discovery purposes and allows Regen to share structural information on compounds of mutual interest.

In addition, the company has completed pre-clinical research indicating that, by inhibiting NR2F6, cancer stem cells can be converted into normal cells, thus potentially curing the patient of cancer. Additionally, activators of NR2F6 have the potential to provide relief from autoimmune diseases such as arthritis.